Home » News Events » APOE Webinar - Thursday 14th May 2020

Perivascular Spaces in Small vessel Disease Research Network would like to invite anyone to attend a webinar organised by the Cure Alzheimer's Fund. The main topic is focused on apolipoprotein E (APOE), blood–brain barrier dysfunction and cognitive decline. The webinar will take place on Thursday, 14th of May 2020.

Please note that the event sessions will take place at  EDT local time.

Zoom access information


Password: CureAlz

iPhone one-tap:  US: +16465588656,,89468515435#,,1#,911839#  or +13017158592,,89468515435#,,1#,911839# 

Callers will not be able to submit questions because the Q&A function requires a computer

Dial (for higher quality, dial a number based on your current location):

US: +1 646 558 8656  or +1 301 715 8592  or +1 312 626 6799  or +1 669 900 9128  or +1 253 215 8782  or +1 346 248 7799 

    Webinar ID: 894 6851 5435

    Password: 911839

International numbers available: https://us02web.zoom.us/u/kAqxKQEbo


Event Schedule (please note these are project titles and talk topics may be more expansive):

12:45 – 12:55pm

Meg Smith (CureAlz)



12:55 – 1:15pm

Christian Pike, Ph.D. (USC), and Caleb Finch, Ph.D. (USC)

Interactions among TREM2, APOE, and sex


1:15 – 1:35pm          

Jean-Pierre Roussarie, Ph.D. (Rockefeller)

Fleming APOE Consortium: Regulation by APOE of selective neuronal vulnerability to Alzheimer’s


1:35 – 1:55pm

Oleg Butovsky, Ph.D. (Brigham and Women’s Hospital)

Fleming APOE Consortium: The role of APOE in microglia regulation in neurodegeneration


1:55 – 2:00pm            Break


2:00 – 2:20pm          

Berislav Zlokovic, M.D., Ph.D. (USC)

Molecular Signatures of APOE-Mediated Blood-Brain Barrier Dysfunction Causing Neuronal and Synaptic Dysfunction


2:20 – 2:40pm          

Randall Bateman, M.D. (WUSTL)

Fleming APOE Consortium: Assessing the added diagnostic value of peripheral ApoE protein levels in current blood-based biomarker assays for CNS amyloidosis


2:40 – 3:00pm          

David Holtzman, M.D. (WUSTL)

Fleming APOE Consortium: Understanding the effect of apoE on tau-mediated neurodegeneration


3:00 – 3:20pm

Daniel Laskowitz, M.D., M.H.S. (Duke)

A novel apoE mimetic therapeutic peptide CN-105 attenuates AD pathology and improves functional outcomes in a murine model of Alzheimer’s disease


3:20 – 3:40pm

Cheryl Wellington, Ph.D. (UBC)

Fleming APOE Consortium: Toward developing high density lipoprotein enriched in apolipoprotein E as a potential biomarker and therapeutic targeting vascular contributions to Alzheimer’s disease


3:40 – 4:00pm

Guojun Bu, Ph.D. (Mayo Jacksonville)

Fleming APOE Consortium: Counteracting Pathogenic Events in AD with Peripheral or Central ApoE


4:00 – 4:30pm

Li-Huei Tsai, Ph.D. (MIT), and Kellis, Manolis, Ph.D. (MIT)

Collaboration to Infer Regulatory Circuits and to Uncover Innovative Therapeutic Strategies